JP2013522311A5 - - Google Patents

Download PDF

Info

Publication number
JP2013522311A5
JP2013522311A5 JP2013500162A JP2013500162A JP2013522311A5 JP 2013522311 A5 JP2013522311 A5 JP 2013522311A5 JP 2013500162 A JP2013500162 A JP 2013500162A JP 2013500162 A JP2013500162 A JP 2013500162A JP 2013522311 A5 JP2013522311 A5 JP 2013522311A5
Authority
JP
Japan
Prior art keywords
phe
lys
arg
aromatic
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013500162A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013522311A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/028543 external-priority patent/WO2011116007A1/en
Publication of JP2013522311A publication Critical patent/JP2013522311A/ja
Publication of JP2013522311A5 publication Critical patent/JP2013522311A5/ja
Pending legal-status Critical Current

Links

JP2013500162A 2010-03-15 2011-03-15 シクロスポリンおよび芳香族カチオン性ペプチドを用いた併用療法 Pending JP2013522311A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31394510P 2010-03-15 2010-03-15
US61/313,945 2010-03-15
US37681310P 2010-08-25 2010-08-25
US61/376,813 2010-08-25
PCT/US2011/028543 WO2011116007A1 (en) 2010-03-15 2011-03-15 Combination therapies using cyclosporine and aromatic cationic peptides

Publications (2)

Publication Number Publication Date
JP2013522311A JP2013522311A (ja) 2013-06-13
JP2013522311A5 true JP2013522311A5 (https=) 2014-05-01

Family

ID=44649559

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013500162A Pending JP2013522311A (ja) 2010-03-15 2011-03-15 シクロスポリンおよび芳香族カチオン性ペプチドを用いた併用療法

Country Status (4)

Country Link
US (4) US8697657B2 (https=)
EP (6) EP3375449A1 (https=)
JP (1) JP2013522311A (https=)
WO (1) WO2011116007A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3090754A1 (en) * 2009-12-31 2016-11-09 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
EP3266462A1 (en) * 2009-12-31 2018-01-10 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
EP3375449A1 (en) 2010-03-15 2018-09-19 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
EP2590664B1 (en) * 2010-07-09 2019-03-27 Stealth Peptides International, Inc. Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury
CN106913860A (zh) 2011-09-29 2017-07-04 梅约医学教育与研究基金会 芳族阳离子肽和使用它们的方法
EP2788013A4 (en) * 2011-12-09 2015-08-19 Stealth Peptides Int Inc AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
CN104271146A (zh) * 2012-03-30 2015-01-07 康肽德生物医药技术有限公司 用于预防和治疗神经病的方法和组合物
JP2014196281A (ja) * 2012-08-01 2014-10-16 健輔 江頭 医薬組成物
JP2015529655A (ja) 2012-08-02 2015-10-08 ステルス ペプチドズ インターナショナル インコーポレイテッド アテローム性硬化症の処置方法
AU2013334788A1 (en) * 2012-10-22 2015-06-04 Henry Ford Health Systems Methods for reducing risks associated with heart failure and factors associated therewith
JP2016506391A (ja) * 2012-12-06 2016-03-03 ステルス ペプチドズ インターナショナル インコーポレイテッド ペプチド治療薬およびその使用方法
ES2755134T3 (es) 2013-03-01 2020-04-21 Stealth Biotherapeutics Corp Métodos para el tratamiento de enfermedad mitocondrial
US9687519B2 (en) 2013-03-01 2017-06-27 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
WO2014165607A2 (en) * 2013-04-02 2014-10-09 Stealth Peptides International, Inc. Aromatic-cationic peptide formulations, compositions and methods of use
EP3586864A1 (en) * 2013-05-14 2020-01-01 Stealth Biotherapeutics Corp Methods for the prevention or treatment of left ventricle remodeling
US20140363391A1 (en) * 2013-06-06 2014-12-11 Demetris Yannopoulos System and method for administering poloxamers and anesthetics while performing cpr and minimizing reperfusion injury
WO2014210062A1 (en) 2013-06-26 2014-12-31 Stealth Peptides International, Inc. Methods for the regulation of matrix metalloproteinase expression
CA2916977A1 (en) 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
WO2014210056A1 (en) * 2013-06-27 2014-12-31 Stealth Peptides International, Inc. Peptide therapeutics and methods for using same
CA2920735A1 (en) * 2013-08-12 2015-02-19 Stealth Biotherapeutics Corp Combination therapy for the treatment of ischemia-reperfusion injury
US10221213B2 (en) 2013-12-27 2019-03-05 Stealth Biotherapeutics Corp Pharmaceutically relevant aromatic-cationic peptides
JP2017512762A (ja) * 2014-03-03 2017-05-25 ステルス バイオセラピューティックス コープ 薬学的に妥当な芳香族カチオン性ペプチド及びその生成方法
EP3502132A1 (en) * 2014-05-28 2019-06-26 Stealth BioTherapeutics Corp Therapeutic compositions including therapeutic small molecules and uses thereof
WO2015183984A2 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including tocopherol and uses thereof
WO2015183995A2 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
CA2958585C (en) * 2014-08-21 2024-01-09 Stealth Biotherapeutics Corp Use of peptide d-arg-2',6'-dmt-lys-phe-nh2 for the treatment of alport syndrome
US10683534B2 (en) * 2015-01-27 2020-06-16 BioSpyder Technologies, Inc. Ligation assays in liquid phase
CA2976632A1 (en) * 2015-02-13 2016-08-18 Stealth Biotherapeutics Corp Therapeutic compositions including mitochondrial fission inhibitor peptides, variants thereof and methods of using the same
EP3265109B1 (en) 2015-03-06 2020-10-21 Stealth BioTherapeutics Corp Processes for preparing pharmaceutically relevant peptides
CA3006698A1 (en) * 2015-11-30 2017-06-08 Peter Schiller Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
CA3017359A1 (en) 2016-03-11 2017-09-14 Scott M. Duncan Crystalline salt forms
US11034724B2 (en) 2017-04-05 2021-06-15 Stealth Biotherapeutics Corp. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
US11325943B2 (en) * 2017-06-02 2022-05-10 Stealth Biotherapeutics Inc. Crystalline salt forms of SBT-20
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
US12252554B2 (en) 2018-12-18 2025-03-18 Stealth Biotherapeutics Inc. Analogs that target mitochondrial diseases
IL284006B2 (en) * 2018-12-18 2024-12-01 Stealth Biotherapeutics Corp Mitochondria-targeting peptides
CN111449050A (zh) * 2019-01-20 2020-07-28 睿诺医疗科技（上海）有限公司 环孢菌素类似物及其用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5786332A (en) * 1995-03-06 1998-07-28 Trega Biosciences, Inc. Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels
SE520730C2 (sv) * 1995-01-20 2003-08-19 Eskil Elmer Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
WO2000051625A1 (en) 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
SE9900961D0 (sv) * 1999-03-16 1999-03-16 Astra Ab Novel compounds
US6593292B1 (en) * 1999-08-24 2003-07-15 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
EP1599216B9 (en) 2003-02-04 2015-02-11 Cornell Research Foundation, Inc. Methods for preventing mitochondrial permeability transition
CA3024434A1 (en) * 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
WO2005097164A2 (en) * 2004-04-08 2005-10-20 Novartis Ag Use of cyclosporins for treatment of cerebral ischemia and brain and spinal cord injury
EP2023948A1 (en) * 2006-05-04 2009-02-18 Michel Ovize Use of cyclosporin a or melle4-cyclosporin for the treatment of acute myocardial infarction
EP2114427B1 (en) * 2007-01-30 2014-06-25 New York University Peptides for treatment of conditions associated with nitric oxide
EP3741381B1 (en) 2008-02-26 2024-04-24 Cornell University A peptide for use for prevention and treatment of acute renal injury
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
EP2376524B1 (en) * 2008-12-31 2017-03-15 Cypralis Limited Derivatives of cyclosporin a
ES2964555T3 (es) * 2009-08-24 2024-04-08 Stealth Biotherapeutics Inc Péptido para uso en la prevención o tratamiento de la degeneración macular
EP3266462A1 (en) 2009-12-31 2018-01-10 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
EP3090754A1 (en) * 2009-12-31 2016-11-09 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
CA2787331A1 (en) 2010-01-25 2011-07-28 Hazel H. Szeto Aromatic-cationic peptides and uses of same
JP2013521231A (ja) * 2010-02-26 2013-06-10 ユニバーシティ オブ フロリダ リサーチ ファウンデーション インコーポレイテッド ミトコンドリア標的化抗酸化剤は機械的人工呼吸誘発性横隔膜機能障害および骨格筋萎縮を防止する
EP3375449A1 (en) * 2010-03-15 2018-09-19 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides

Similar Documents

Publication Publication Date Title
JP2013522311A5 (https=)
CA2915005C (en) Use of eribulin and lenvatinib as combination therapy for treatment of cancer
ES2425083T3 (es) Agente antitumoral que comprende FK228 como inhibidor de histona desacetilasa y doxorrubicina como inhibidor de topoisomerasa II
ES2398012T5 (es) Lixisenatide como terapia complementaria a insulina glargina y metformina para tratar diabetes de tipo 2
ES2484315T3 (es) Tratamiento de la pérdida del sentido del tacto con derivados de saxitoxina
JP2009102342A5 (https=)
JP2011500851A5 (https=)
JP2011241213A5 (https=)
JP2013515739A5 (https=)
ES2922551T3 (es) Tratamiento de pacientes con diabetes mellitus tipo 2
RU2013139651A (ru) Новые соединения, влияющие на пищевое поведение
JP2015522630A5 (https=)
TW201601743A (zh) 外周ｋａｐｐａ鴉片受體促進劑用於製備預防、抑制或治療噁心及嘔吐之藥物的用途
JP2013518124A5 (https=)
JP2020510043A5 (https=)
JP2009500045A5 (https=)
WO2009151714A3 (en) Therapeutic for treatment of circulatory shock, ischemia, inflammatory disease and related conditions
ES2267841T3 (es) Uso de una derivado de alfa-halogeno-acriloil distamicina para la preparacion de un medicamento para el tratamiento del cancer.
CA2582452A1 (en) Pegylated liposomal doxorubicin in combination with ecteinascidin 743
IL194500A0 (en) Peptide substance enhancing capillaries resistance, pharmaceutical composition on its base and method of its application
TWI496579B (zh) 類鋅手指胜肽、其表現質體、及包含其之醫藥組成物之用途
ES2671024T3 (es) Composición farmacéutica para administración transnasal
BR112019026336A2 (pt) forma de sal de cloridrato de um peptídeo análogo da porção c-terminal de c5a e o uso da mesma, composição, método para induzir uma resposta imune contra uma infecção ou câncer, kit e composto para aumentar uma resposta imune para um agente imunogênico
WO2021216678A1 (en) Renin-angiotensin system (ras) modulators for treatment of viral infections, pharmaceutical compositions including the same
CN114364691B (zh) 作为纤维化基质积累的抑制剂的肽